Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Jia Ruan, MD, PhD
Conference Coverage
Advances in Chemoimmunotherapy for Frontline Mantle Cell Lymphoma Treatment
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD
Conference Coverage
Advances in Chemoimmunotherapy for Frontline Mantle Cell Lymphoma Treatment
03/01/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress, Jia Ruan, MD, PhD, discusses advances in chemoimmunotherapy for the first-line treatment of patients with mantle cell lymphoma.
At the Lymphoma, Leukemia &...
03/01/2024
Lymphoma, Leukemia & Myeloma Network
Nicole Lamanna, MD
Conference Coverage
Exploring Potential Options for Treating Patients With Chronic Lymphocytic Leukemia With Pirtobrutinib
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network
Nicole Lamanna, MD
Conference Coverage
Exploring Potential Options for Treating Patients With Chronic Lymphocytic Leukemia With Pirtobrutinib
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network
Nicole Lamanna, MD
Conference Coverage
Exploring Potential Options for Treating Patients With Chronic Lymphocytic Leukemia With Pirtobrutinib
02/29/2024

Featuring Nicole Lamanna, MD

Featuring Nicole Lamanna, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.
At the Lymphoma, Leukemia &...
02/29/2024
Lymphoma, Leukemia & Myeloma Network
Neil Kay, MD, Mayo Clinic
Conference Coverage
Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia
02/27/2024

Featuring Neil E. Kay, MD

Featuring Neil E. Kay, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia &...
02/27/2024
Lymphoma, Leukemia & Myeloma Network
Neil Kay, MD, Mayo Clinic
Conference Coverage
Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia
02/27/2024

Featuring Neil E. Kay, MD

Featuring Neil E. Kay, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia &...
02/27/2024
Lymphoma, Leukemia & Myeloma Network
Neil Kay, MD, Mayo Clinic
Conference Coverage
Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia
02/27/2024

Featuring Neil E. Kay, MD

Featuring Neil E. Kay, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.
At the Lymphoma, Leukemia &...
02/27/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network
Ajai Chari, MD
Conference Coverage
Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment
02/23/2024

Featuring Ajai Chari, MD

Featuring Ajai Chari, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...
At the Lymphoma, Leukemia &...
02/23/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

Advertisement

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use